Document Detail

Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
MedLine Citation:
PMID:  18082493     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Pentraxin 3 (PTX3) is a novel inflammatory marker produced by endothelial cells, smooth muscle cells, and macrophages. The purpose of the present study was to examine the clinical significance of plasma PTX3 levels in patients with heart failure. METHODS: We measured the plasma PTX3 levels in 196 patients with heart failure and 60 control subjects without heart failure by sandwich enzyme-linked immunosorbent assay. Patients were prospectively followed during a median follow-up period of 655 days with the end points of cardiac death or progressive heart failure requiring rehospitalization. RESULTS: Plasma PTX3 concentrations were higher in patients with heart failure than in control subjects (P < .0001) and increased as the severity of New York Heart Association functional class advanced (P < .0001). A total of 63 cardiac events occurred during a follow-up period, and cardiac event-free rate was markedly lower in patients with high PTX3 levels than in those with normal PTX3 levels (44.7% vs 89.2%, P < .0001). The multivariate Cox proportional hazard analysis demonstrated that the plasma PTX3 level, but not the high-sensitive C-reactive protein, was the independent predictor of cardiac events (hazard ratio 1.20, 95% CI 1.03-1.40, P = .0162). Patients were divided into 4 groups based on plasma PTX3 values from first to fourth quartile. The highest fourth quartile of plasma PTX3 levels was associated with the highest risk of cardiac events (9.23-fold compared with the first quartile). CONCLUSIONS: The plasma PTX3 level provides important prognostic information for the risk stratification of patients with heart failure.
Satoshi Suzuki; Yasuchika Takeishi; Takeshi Niizeki; Yo Koyama; Tatsuro Kitahara; Toshiki Sasaki; Mina Sagara; Isao Kubota
Related Documents :
15389243 - Electrocardiogram and b-type natriuretic peptide as screening tools for left ventricula...
14998613 - Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute m...
22475273 - Risk of congenital heart defects is influenced by genetic variation in folate metabolism.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-09-27
Journal Detail:
Title:  American heart journal     Volume:  155     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2007-12-17     Completed Date:  2008-01-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  75-81     Citation Subset:  AIM; IM    
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
C-Reactive Protein / analysis*
Case-Control Studies
Disease Progression
Heart Failure / blood,  diagnosis*,  mortality*
Inflammation Mediators / blood*
Middle Aged
Predictive Value of Tests
Proportional Hazards Models
Reference Values
Risk Assessment
Sensitivity and Specificity
Serum Amyloid P-Component / analysis*
Severity of Illness Index
Statistics, Nonparametric
Survival Analysis
Vasculitis / blood*
Reg. No./Substance:
0/Inflammation Mediators; 0/Serum Amyloid P-Component; 148591-49-5/PTX3 protein; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an in...
Next Document:  Cystatin C and risk of heart failure in the Physicians' Health Study (PHS).